SubHero Banner

Mavenclad® (cladribine) – New drug approval

March 29, 2019 - The FDA announced the approval of EMD Serono’s Mavenclad (cladribine), for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Due to its safety profile, use of Mavenclad is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of MS.

Download PDF